Paramedic PapersHome Paediatrics Intranasal dexmedetomidine paediatric sedation
Paediatrics
Intranasal dexmedetomidine paediatric sedation
Intranasal Dexmedetomidine for Paediatric Procedural Sedation in the Emergency Department: A Single‐Centre Retrospective Observational Cohort Study
Emergency Medicine Australasia · Added 22 September 2026
Townsville cohort of 114 children given intranasal dexmedetomidine for ED procedural sedation — effective as a sole agent in 78%, adverse events in 13% (mostly mild bradycardia), but ED stays ran long at a median 395 minutes
- Study type
- Cohort
- Design
- Single-centre retrospective observational cohort after guideline implementation
- Participants
- 114 children aged 1–16 years in Townsville ED
- Main finding
- IN dexmedetomidine successful as sole agent in 78.1% (95% CI 69.6–84.7%); adverse events 13.2%, mostly mild bradycardia; median ED length of stay 395 min; younger age associated with higher success (aOR 0.86 per year)
- Caveat
- Single-centre retrospective design with incomplete documentation of sedation depth and satisfaction
- Bottom line
- Hypothesis-generating
Why it matters in Australia (Low relevance). transferability — intranasal dexmedetomidine isn't in the ACTAS formulary and procedural sedation stays in ED hands — interesting Australian evidence should a scope debate ever arrive
Learning goal
Weigh intranasal dexmedetomidine against other sedation options for paediatric procedural sedation in my practice.
More
- Topic: Paediatrics
- Daily scan: 22 September 2026
Related papers on Paediatrics
-
Post-ROSC PaCO2 doesn't predict paediatric OHCA outcome
Japanese multicentre registry study of 215 paediatric OHCA patients testing whether the first post-ROSC PaCO2 category predicts 30-day outcomes — no clear association with favourable neurologic outcome or survival for either hypocapnia (aOR 0.83) or hypercapnia (aOR 1.46), though estimates were imprecise with wide confidence intervals.
-
Paediatric air medical intubation performance
US national cohort of 1,040 paediatric air medical intubations — 86.5% first-pass success overall but only 69.1% in infants under 1, with ketamine the commonest induction agent and substantial site-to-site variation
-
Paediatric IV ketamine sedation very safe
Systematic review of 20 studies covering 67,871 children having IV ketamine procedural sedation in EDs — no deaths or permanent adverse outcomes, sentinel events pooled at about 1 in 11,558 sedations, serious adverse events 0.34%, with age ≥10, upper respiratory infection and opioid co-administration modest predictors while ASA status and benzodiazepine co-administration were not.
-
Anonymous video deletion biased newborn RCT
Norwegian analysis of the NeoBeat RCT testing whether anonymous staff deletion of resuscitation videos introduced selection bias — after the anonymous opt-out, enrolled newborns had significantly higher Apgar scores, shorter ventilation and fewer admissions, and the trial was terminated halfway without power to conclude on its outcomes.